HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma

Abstract

Aims—To clarify the role of human papillomavirus (HPV) infection in the development of papilloma, dysplasia, squamous cell carcinoma, and basal cell epitheloma arising from the eyelids, including the tunica conjunctiva palpebrum (conjunctiva), its junction to epithelium of eyelid skin (junction), and eyelid skin.

Methods—Sixteen cases of papilloma, four of dysplasia, four of squamous cell carcinoma, and 12 of basal cell epitheloma were examined using formalin fixed and paraffin embedded samples. Detection of HPV-DNA was performed by PCR-RFLP and in situ hybridisation (ISH) methods.

Results—HPV-16 was detected in 12/16 papillomas (75%), 2/4 dysplasias (50%), and 1/4 squamous cell carcinomas (25%) but in none of the basal cell epitheliomas. No other HPV subtypes were found. ISH assay showed positive signals in only two cases of dysplasia and squamous cell carcinoma. The mean age of HPV-16 positive dysplasia and squamous cell carcinoma cases (81.7 years) was significantly higher than that of HPV-16 positive papilloma cases (p<0.01).

Conclusions—Based on the presence of HPV-16 in both benign and malignant lesions and the age distribution, it seems likely that HPV-16 alone may be incapable of causing development of conjunctival and junctional dysplasia and squamous cell carcinoma, and that any correlation between the papilloma–squamous cell carcinoma sequence and HPV infection may be due to rare events.

(J Clin Pathol 1995;48:1106–1110)

Keywords: HPV, conjunctiva, papilloma, squamous cell carcinoma.

The human papillomavirus (HPV), a representative member of the oncogenic viruses, is composed of closed circular double stranded DNA of approximately 8 kb in length. Its occurrence is closely related to squamous proliferative lesions of the cervix, anogenital region, skin, and upper respiratory and digestive tracts. Over 50 types of HPV have been identified to date and some have been shown to play an important role in the development of tumour lesions. For example, in mucosal-squamous epithelium of uterine cervix and vulva, HPV-6 and HPV-11 induce benign papillomatous lesions, and HPV-16 and HPV-18 are closely linked with progression to malignancy.

Earlier studies have implicated HPV infection in the pathogenesis of conjunctival papillomas because of the frequent finding of koilocytic features in these lesions. More recently, the presence of HPV capsid antigens and DNA sequence has been documented in conjunctival neoplasms, including papillomas, dysplasia, and squamous cell carcinomas.

However, no detailed examination of the correlation between HPV infection and benign and malignant lesions originating from the eyelid area has so far been described.

In the present study, to clarify the exact role of HPV infection in tumour development, papillomas, basal cell epitheliomas, dysplasia, and squamous cell carcinomas arising from eyelids—including the tunica conjunctiva palpebrum, its junction between the conjunctival mucosa and the epidermis of eyelid skin, and the eyelid skin itself—were examined using molecular biological and clinicopathological methods.

Methods

CASE SELECTION AND DNA EXTRACTION

Sixteen cases of papilloma, 12 of basal cell epithelioma, four of dysplasia, and four of squamous cell carcinomas surgically removed from the eyelid area, including the tunica conjunctiva palpebrum (conjunctiva), its junction to eyelids epidermis (junction), and the eyelid skin, were selected from patient files of the Kitasato university hospital for the years 1979 to 1994. All resected samples had been fixed in 10% formalin and embedded in paraffin.

DNA samples for the detection of HPV-DNA were obtained by scraping off tumour cells identified on several serial 10 μm thick paraffin sections. DNA extraction was performed through phenol/chloroform treatment as described previously.

POLYMERASE CHAIN REACTION ASSAY

For the detection of HPV-DNA, consensus primers for the HPV L1 region, L1C1 and L1C2, published by Yoshikawa et al., were used. These can differentiate nine species of HPV, including types 6, 11, 16, 18, 31, 33, 42, 52, and 58. Polymerase chain reaction (PCR) mixture (10 μl) containing 1 ng template DNA, 100 nM of each primer, and 0.5 unit of Taq DNA polymerase (Takara) was prepared. The PCR procedure consisted of 45 cycles of 30
out at 37°C overnight. Hybridisation signals were detected according to the manufacturer’s instructions. As positive control, fluorescein labelled human genomic DNA was used, and a pUC plasmid vector was examined as negative control.

STATISTICS
Statistical analysis of data was performed using the Mann-Whitney U test.

Results
PCR ASSAY
Amplified specific HPV DNA was detected in 12 of the 16 papilloma cases (75%). Five lesions of these 12 HPV-DNA-positive cases were located in the conjunctiva, and seven were from the junction. Two of four dysplasia cases (50%) (one from the conjunctiva, and the other from the junction), and one of four squamous cell carcinoma cases (originating from the junction) also showed the presence of HPV-DNA (fig 1). No HPV-DNA was noted in basal cell epithelioma cases.

RFLP assay revealed that all amplified HPV DNAs were from HPV-16, since all PCR products digested with Dde I, Dde II, and Hae III, and HPV subtypes were determined by restriction fragment length polymorphism (RFLP).

The quality of the DNA extracted was confirmed before starting the study using β globin gene specific primers. PCR was performed as a replicate or triplicate assay. DNA available from uterine cervical carcinoma cases and proven to be positive for HPV-16 or HPV-18 was used as positive control, and water instead of DNA was used for negative control.

IN SITU HYBRIDISATION PROCEDURE
The probe used for the in situ hybridisation was a fluorescein labelled DNA probe for wide spectrum HPV DNA (Dako), and an in situ hybridisation detection system was applied. Briefly, samples were digested with 0-8% pepsin/0·2 N HCl, and hybridisation was carried

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age and sex</th>
<th>Lesion</th>
<th>HPV type*</th>
<th>ISH</th>
<th>Koilocytosis</th>
<th>Parakeratosis</th>
<th>Hyperkeratosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23, F</td>
<td>Conj</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>2</td>
<td>22, F</td>
<td>Conj</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>3</td>
<td>24, M</td>
<td>Conj</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>4</td>
<td>53, M</td>
<td>Conj</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>5</td>
<td>53, F</td>
<td>Conj</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>6</td>
<td>23, F</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>14, M</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>25, F</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>9</td>
<td>47, F</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>10</td>
<td>41, F</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>11</td>
<td>40, F</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>12</td>
<td>40, M</td>
<td>Jun</td>
<td>16</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>13</td>
<td>59, M</td>
<td>Jun</td>
<td>−</td>
<td>ND</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>14</td>
<td>73, F</td>
<td>Jun</td>
<td>−</td>
<td>ND</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>15</td>
<td>51, F</td>
<td>Jun</td>
<td>−</td>
<td>ND</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>16</td>
<td>22, F</td>
<td>Jun</td>
<td>−</td>
<td>ND</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

* HPV subtype was determined by PCR-RFLP assay. ISH = in situ hybridisation; Conj = conjunctiva; Jun = junction between conjunctival epithelium and eyelid epidermis; ND = not done.
For the HPV-16-positive cases the age range was from 14 to 53 years (mean 33.8) and for negative cases from 22 to 73 years (mean 51.3), with no significant difference between the ages (p = 0.16). In contrast, the ages of dysplasia and squamous cell carcinoma cases ranged from 49 to 85 years (mean 74.8). The mean age of HPV-16-positive dysplasia and squamous cell carcinoma cases (81-7 years) was significantly higher than that of the HPV-16-positive papilloma cases (p < 0.01). Neither the male to female ratio nor the localisation of the tumour in the conjunctiva or the junction showed any link to HPV-16. The data on the squamous cell carcinoma and dysplasia cases are summarised in table 2.

The histopathological features of koilocytosis, which is characterised by hyperchromatism and creation of the nuclei with perinuclear clearing of the cytoplasm, were found in only six HPV-16-positive junctional papilloma cases, and thin parakeratotic changes in proliferating squamous epithelium were noted in six of the 12 HPV-DNA-positive papilloma cases (two from the conjunctiva and four from the junction) (fig 3). All cases of HPV-DNA-negative papillomas showed hyperkeratotic figures but there was no koilocytosis. Of the four squamous cell carcinoma cases, the HPV-DNA-positive lesion was well differentiated, and the three negative cases were moderately or poorly differentiated.

Discussion

The eyelid is anatomically composed of the tunica conjunctiva palpebrum, its junction to the eyelid epidermis, and the eyelid skin itself. It is known that conjunctival papillomas frequently contain goblet cells—usually showing a tendency to epidermalisation and keratinisation of moderate degree—and that papillomatous eyelid skin consists of hyperplastic squamous epithelium, which shows acanthosis, parakeratosis, and hyperkeratosis. In the present study, HPV-16-positive junctional papilloma cases showed koilocytic and thin parakeratotic features, while HPV-16-negative cases showed hyperkeratotic figures without koilocytosis. Considering that HPV-16 is capable of infecting the conjunctival mucosa, it may thus be possible to determine histopathologically the origin (mucosa or epidermis) of junctional papillomas and the presence or absence of HPV.

Earlier studies have demonstrated a close linkage between conjunctival papillomas and HPV-6 and HPV-11 infection.13,14 McDonnell et al,15 using in situ hybridisation, found that 15 of 23 cases of conjunctival papilloma (65.2%) had HPV-6. Moreover, 13 out of 15 positive cases (86.7%) were under the age of 30 years, suggesting that infection with HPV-6 may be responsible for most of the conjunctival papillomas occurring in children and young adults. In the present PCR-RFLP assay study, HPV-16 was detected in conjunctival and junctional papillomas, but not HPV6/11. The PCR assay is able to detect even a single copy of target DNA, although there are serious problems with possible contamination. To avoid false positive or negative results, we conducted PCR as a replicate or triplicate assay, also providing several negative controls. The RFLP assay applied in this study is very reliable for determination of HPV subtyping, since the various restriction enzyme sites in amplified specific HPV DNA L1 region sequences clearly differ with the HPV subtype. Therefore, it seems possible that HPV-16 is causally related to conjunctival papillomas. The discrepancy between this and

---

**Table 2 Data summary of SCC and dysplasia cases**

<table>
<thead>
<tr>
<th>Case no</th>
<th>Age and sex</th>
<th>Lesion</th>
<th>Histology</th>
<th>HPV type*</th>
<th>ISH</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>82, F</td>
<td>Jun</td>
<td>Mod SCC</td>
<td>–</td>
<td>ND</td>
</tr>
<tr>
<td>2</td>
<td>75, F</td>
<td>Jun</td>
<td>Mod SCC</td>
<td>–</td>
<td>ND</td>
</tr>
<tr>
<td>3</td>
<td>85, F</td>
<td>Jun</td>
<td>Well SCC</td>
<td>16</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>70, M</td>
<td>Jun</td>
<td>Poor SCC</td>
<td>–</td>
<td>ND</td>
</tr>
<tr>
<td>5</td>
<td>83, F</td>
<td>Jun</td>
<td>Dysplasia</td>
<td>16</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>77, M</td>
<td>Conj</td>
<td>Dysplasia</td>
<td>–</td>
<td>ND</td>
</tr>
<tr>
<td>7</td>
<td>49, M</td>
<td>Conj</td>
<td>Dysplasia</td>
<td>–</td>
<td>ND</td>
</tr>
<tr>
<td>8</td>
<td>77, M</td>
<td>Conj</td>
<td>Dysplasia</td>
<td>16</td>
<td>+</td>
</tr>
</tbody>
</table>

* HPV subtype was determined by PCR-RFLP assay. ISH = in situ hybridisation; Conj = conjunctival; Jun = junction between conjunctival epithelium and eyelid epidermis. Well = well differentiated; Mod = moderately differentiated; Poor = poorly differentiated; SCC = squamous cell carcinoma; ND = not done.
has been estimated that about 50 to 100 viral copies per cell are required. False negative reactions could therefore be caused by low levels of viral replication, as well as inappropriate tissue fixation and processing. This would explain the discrepant results between polymerase chain reaction and in situ hybridisation assays in this study, since the PCR-RFLP technique is more sensitive.

It has been suggested that HPV alone cannot completely transform primary human keratinocytes or other cells, but that addition of mutational activated v-Ha-ras to HPV-16 immortalized human cervical cells results in full malignant transformation. zur Hausen has suggested that HPV may act as a promotor-like agent in synergism with carcinogenic initiators such as cigarette smoke or herpes simplex virus in the development of cervical neoplasia.

The oncogenic role of HPV in conjunctival neoplasms has been recently discussed. McDonnell et al. using polymerase chain reaction and dot blot hybridisation methods, showed that HPV16 was present in 37 out of 42 conjunctival epithelial lesions (88.1%), including mild to severe dysplasias and invasive carcinomas, suggesting that the interaction of HPV with ultraviolet light or some other element plays an important role in the development of neoplasia at this site. In addition, Wilson and Ostler stated that conjunctival papilloma can be divided into two groups, infected and non-infected, the non-infected papillomas—probably related to ultraviolet light exposure—being capable of undergoing malignant transformation. Recently, Ateiyy-Agaba indicated that the combination of human immunodeficiency virus (HIV) induced immunosuppression, HPV infection, and intense exposure to ultraviolet light may accelerate the development of squamous cell carcinoma. Our results show that HPV-16 infection is associated with dysplasia and squamous cell carcinoma but not basal cell epithelioma. In addition, most of the dysplasia and squamous cell carcinoma cases were older than 70 years, with a mean age greater than that of HPV-16-positive papilloma cases. Based on the presence of HPV-16 in both benign and malignant lesions and its age distribution, it seems likely that HPV-16 alone may be incapable of inducing conjunctival and junctional dysplasia and squamous cell carcinoma, and that any correlation between the papilloma-squamous cell carcinoma transition and HPV infection may be due to rare events. Further studies are indicated to explore the relation between HPV-16 infection and other carcinogenic agents in the development of conjunctival and junctional dysplasia and squamous cell carcinoma.

Previous studies may be due to the age of cases investigated, since half of the HPV-16-positive papilloma cases in this study were older than 40 years.

In order to detect HPV signals by in situ hybridisation using radioactive DNA probes, it

Figure 3(A) HPV-16-positive conjunctival papilloma (case 5) showing typical histology, including the presence of goblet cells and a tendency to epidermalisation. H and E, x 175. (B) HPV-16-positive junctional papilloma (case 6). Koilocytic (arrows) and thin parakeratotic (upper left side) features are present. H and E, x 175. (C) HPV-negative junctional papilloma (case 16) showing papillomatosis, hyperkeratosis, and the absence of koilocytosis. H and E, x 175.

19 zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events. Lancet 1982;i:1370–2.
HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma.

M Saegusa, Y Takano, M Hashimura, I Okayasu and J Shiga

doi: 10.1136/jcp.48.12.1106

Updated information and services can be found at:
http://jcp.bmj.com/content/48/12/1106

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/